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ntravascular Ultrasound Molecular
maging of Atheroma Components In Vivo
ndrew J. Hamilton, MD,* Shao-Ling Huang, PHD,† Drew Warnick, BS,* Mark Rabbat, BS,*
onnie Kane, BS,* Ashwin Nagaraj, PHD,* Melvin Klegerman, PHD,‡ David D. McPherson, MD*
hicago and Evanston, Illinois; and College Park, Maryland
OBJECTIVES Our purpose was to quantitate and confirm specific echogenic immunoliposome (ELIP)
atheroma component enhancement in vivo.
BACKGROUND Targeted ELIPs for ultrasonic detection and staging of active molecular components of
endothelium and atheroma have been developed.
METHODS In Yucatan miniswine, the endothelium was injured from one femoral and one carotid artery,
and animals were fed a high-cholesterol diet for two months to create various stages of
atheroma. Arteries were imaged with intravascular ultrasound (IVUS) 5 and 10 min after
ELIP injection (5-mg dose). Anti-intercellular adhesion molecule-1 (ICAM-1), anti-vascular
cell adhesion molecule-1 (VCAM-1), anti-fibrin, anti-fibrinogen, and anti-tissue factor (TF)
conjugated ELIPs were used, and immunohistochemistry (IHC) confirmed the presence or
absence of molecular expression. Two blinded observers determined if each segment was
enhanced by ELIP. Three-dimensional image reconstruction and videodensitometric analysis
determined the mean gray-scale (MGS) change of the luminal border.
RESULTS To determine endothelial injury component enhancement, anti-fibrinogen ELIP enhanced
exposed fibrin in all arteries (MGS increased 22  5%; 6 arteries; 2 animals). To determine
enhancement of molecular components in atherosclerotic arteries, observers detected en-
hancement 5 min after anti-VCAM, anti-ICAM, anti-TF, anti-fibrin, and anti-fibrinogen
conjugated ELIPs. Furthermore, ELIP enhanced atheroma MGS by 39 18% (n 8). The
IHC staining confirmed the expression of respective molecular targets in all enhanced
segments.
CONCLUSIONS It was shown that ELIPs specifically enhance endothelial injury/atheroma components. This
allows better characterization of the type and extent of active atheroma components and may
allow more directed therapy. (J Am Coll Cardiol 2004;43:453–60) © 2004 by the
American College of Cardiology Foundationi
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me have developed targeted echogenic immunoliposomes
ELIPs) for ultrasound detection and enhancement of
asoactive and pathologic molecular components of endo-
helium and atheroma (1–3). These ELIPs are small (1
m) ultrasound contrast agents, produced in the absence of
See page 461
dded air, that can be used to evaluate molecular compo-
ents of vasoactive and pathologic endothelium/atheroma
4). Currently available ELIPs are composed of four primary
ipids: phosphatidylcholine (PC), phosphatidylethano-
amine (PE), phosphatidylglycerol (PG), and cholesterol
nd are made using a lyophilization process (5). Once
roduced, the liposomes are conjugated to specific antibod-
From the *Department of Medicine, Feinberg School of Medicine, Northwestern
niversity, Chicago, Illinois; †Department of Biochemistry, Molecular Biology and
ell Biology, Northwestern University, Evanston, Illinois; and ‡EchoDynamics,
ollege Park, Maryland. Supported in part by grant no. HL-59586 from the National
eart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland,
nd the Feinberg Cardiovascular Research Institute, Chicago, Illinois. This study was
resented in part at the American College of Cardiology Scientific Sessions, Atlanta,
eorgia, March 17 to 20, 2002.
Manuscript received March 18, 2003; revised manuscript received July 9, 2003,ccepted July 13, 2003.es that enable targeted ultrasound enhancement of molec-
lar components of atheroma and other tissues (4,6). De-
ection of molecular components may allow staging of
theroma and lead to the development of targeted thera-
eutic interventions.
At the endothelial surface, molecules are expressed
hich, if detected, can help determine the stage or degree of
therosclerosis. For example, endothelium overlying the
houlder region of atherosclerotic lesions expresses vascular
ell adhesion molecule-1 (VCAM-1) and intercellular ad-
esion molecule-1 (ICAM-1) (7). In the early stages of
laque formation, monocytes are recruited to the injured
ndothelial cells by VCAM-1, an important marker of
ndothelial cell activation (8). VCAM-1 is expressed on the
ndothelium of mid-stage atheroma, and its expression
eclines as atheroma progresses (9). ICAM-1 has been
hown to enhance recruitment of circulatory monocytes and
s expressed on the surface of the endothelium in early-stage
theroma (10,11). Fibrin expression within atheroma in
lefts and at the surface of the endothelium is a marker of
nstability of the atherosclerotic plaque and thrombogenesis
12,13). Tissue factor (TF) has also been identified as a
arker of thrombosis formation (14).
The purpose of this study was to demonstrate and
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Molecular IVUS Imaging of Atheroma Components February 4, 2004:453–60onfirm intravascular ultrasound (IVUS) enhancement of
olecular components of atheroma using targeted ELIPs in
single-step process that would allow staging of atheroma.
dditionally, enhancement of atheroma components under
hysiologic flow conditions and confirmation by immuno-
istochemical (IHC) analysis could be evaluated.
ATERIALS
he materials were provided as follows: anti-intracellular
dhesion molecule-1 (Ab 1) (Labvision, Fremont, Califor-
ia) and anti-VCAM-1 (Ab 3) (Dako, Carpinteria, Cali-
ornia); rabbit anti-human anti-fibrinogen (#313R), mono-
lonal anti-fibrin (#350), and anti-TF (American
iagnostica, Greenwich, Connecticut); Fogarty embolec-
omy balloon 4F catheter (Edwards LifeSciences, Irvine,
alifornia); and CVIS 20-MHz IVUS imaging catheter
Boston Scientific, Inc., Sunnyvale, California).
ETHODS
iposome preparation. Echogenic liposomes were made
sing the component lipids: cholesterol, PC, PG, and PE
2). Echogenic liposomes were conjugated to anti-fibrin,
nti-fibrinogen, anti-ICAM-1, anti-VCAM-1, and
nti-TF (15).
Conjugation efficiency was determined by quantitative
mmunoblot and Lowry protein assays (16). Conjugation
fficiency was 7.7 g antibody (Ab)/mg ELIP lipid (20.1
olecules Ab/attamole lipid) for mouse monoclonal anti-
uman fibrin Ab (MAb), 12.5 g Ab/mg lipid (32.6
olecules/amole lipid) for rabbit polyclonal anti-human
brinogen, 11.2 g Ab/mg lipid (29.2 molecules/amole
ipid) for anti-ICAM-1 MAb, 18.2 g Ab/mg lipid (47.5
olecules/amole lipid) for anti-VCAM-1 MAb, and 8.4 g
b/mg lipid (21.9 molecules/amole lipid) for anti-TF
Ab.
The binding affinity (Kassoc) of rabbit anti-fibrin(ogen)
LIP for porcine fibrin was 7.4  107 M1 (avidity index
2.4  109 M1 amole1). Binding was specific, as it was
90% inhibited by the addition of soluble fibrinogen during
Abbreviations and Acronyms
ELIP  echogenic immunoliposome
ICAM-1  intercellular adhesion molecule-1
IHC  immunohistochemistry
IVUS  intravascular ultrasound
M(Ab)  (monoclonal) antibody
MGS  mean gray scale
PC  phosphatidylcholine
PE  phosphatidylethanolamine
PG  phosphatidylglycerol
TF  tissue factor
VCAM-1  vascular cell adhesion molecule-1b-ELIP incubation. Avidity and Kassoc have been reported i15,17,18). We have demonstrated that the ELIP particle
ize after conjugation remained 1 m and, in most cases,
emained between 500 and 800 nm (3).
urgical preparation. The animal protocol was approved
y the Animal Care and Use Committee of Northwestern
niversity. To create atheroma in Yucatan miniswine (20 to
5 kg), a left femoral arteriotomy was performed, a Fogarty
mbolectomy balloon catheter was inserted into the inguinal
igament, and a 3-cm pullback through the artery was
erformed to injure the endothelium. A left common
arotid arteriotomy was performed, and the arterial endo-
helium was similarly injured.
After endothelial injury, the miniswine were fed a high-
holesterol diet (Harlan Teklad test diet) for eight weeks. At
he second surgery, cholesterol levels ranged from 300 to
00 mg/dl (mean 510). In each artery, a 6F sheath was
nserted at least 5 cm distal to the area of imaging for IVUS.
rotocols. PRELIMINARY. To determine visual endothelial
nhancement in two animals, balloon endothelial injury was
erformed in five arteries to increase fibrin/fibrinogen ex-
ression. Anti-fibrinogen conjugated ELIPs were injected
nterarterially with saline injections as controls. An observer
as asked to detect visually enhanced segments.
THEROMA COMPONENT DETERMINATION. In five ani-
als, after atheroma formation, to determine expression of
he molecular targets (VCAM-1, ICAM-1, fibrin, fibrino-
en, or TF), ELIPs conjugated to either anti-VCAM-1,
nti-ICAM-1, anti-fibrin, anti-fibrinogen, or anti-TF were
njected interarterially. Saline and unconjugated ELIP were
ontrols. Staining by IHC confirmed the presence of mo-
ecular targets.
iposome injections. To reduce non-specific binding and
nhancement of previous ELIP injections to another artery,
he type of Ab-conjugated ELIP injected was varied. If no
nhancement was seen with the initial ELIP choice, then a
econd ELIP was chosen and IHC staining was performed
or both molecules.
The dose of conjugated and unconjugated ELIP was
alculated based on the weight of lipid in each sample. The
ose of ELIP used for each artery was 5 mg of lipid. Each
rtery was imaged before and after each injection (at 5 and
0 min).
ntravascular ultrasound imaging. Imaging was per-
ormed with a 20-MHz, high-frequency IVUS imaging
atheter attached to an automatic pullback device that
ithdraws the catheter at 0.5 mm/s. The ileo-femoral
rteries were imaged along their length, and the left and
ight common carotid arteries were imaged from the level of
he aorto-carotid junction to the sheath. Instrument settings
or gain, zoom, compression, and rejection levels were set so
hat the luminal border was just visibly detectable at baseline
or each artery. These settings remained constant through-
ut imaging. Images were recorded onto S-VHS videotape
n real-time for playback and image analysis.
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fter unconjugated or conjugated ELIP injection were
hown simultaneously on two monitors. After every centi-
eter (20 s), the observers were asked if the injured
ndothelium/atheroma was enhanced (), not enhanced
), unsure (/), or uninterpretable (n/a). Enhancement
as defined as a visually brighter or thicker endothelial
nterface, compared with the control.
HREE-DIMENSIONAL RECONSTRUCTION/ANALYSIS. Im-
ges acquired onto videotape were digitized to 640 
80-pixel spatial resolution (0.045 mm/pixel) and 8-bit
256 levels) gray-scale resolution and reconstructed into a
hree-dimensional matrix using EchoPlaque software
version 1.58, Indec Systems, Mountain View, California).
ix longitudinal sections of each artery at 0, 30, 60, 90, 120,
nd 150 degrees were reconstructed.
Areas of enhancement were identified for the control and
LIP injections. Six 3-dimensional images at 0, 30, 60, 90,
20 and 150 degrees were selected. Each three-dimensional
mage had two endothelial surfaces. For each three-
imensional image, an area of interest was created over each
ndothelial-blood interface. The area of interest was drawn
etween the endothelium/atheroma and external elastic
embrane. A gray-scale histogram of the endothelial/
theroma-blood interface was measured, and the mean
ray-scale (MGS) value per pixel was calculated for each
mage using Image-Pro Plus software (version 4.1, Media
ybernetics, Silver Spring, Maryland).
istopathologic analysis. PATHOLOGY. The carotid and
emoral arteries were removed, and each arterial section was
ut into seven equal segments and placed into liquid
itrogen and frozen. Each segment was labeled 1 through 7
igure 1. An immunohistochemistry-stained slide in an early atheroma-in
rown and occurs both in the intima/endothelium and adventitia. Notice1  distal; 7  proximal). The arterial segments were cut ot 4 to 5 m. Sections were fixed in acetone and air dried for
5 to 30 min.
MMUNOHISTOCHEMISTRY. Staining by IHC was per-
ormed according to the Dako EnVision IHC protocol (19).
ntibodies included rabbit anti-human fibrinogen, rabbit
nti-human fibrin, monoclonal anti-ICAM/CD54, anti-
F, and anti-VCAM-1 (Dako Ab, all at 1:100 dilution).
ne artery had staining performed for VCAM-1 and TF
ue to non-enhancement by TF-conjugated ELIP after the
rst injection. A blinded pathologist identified IHC en-
ancement of the target molecule (expressed [], not
xpressed [], or unsure/not assessable [n/a]). Figure 1
emonstrates an IHC-ICAM-stained slide in an early
theroma-induced left femoral artery. Expression of ICAM
ccurs both in the intima/endothelium and within the
dventitia. In nearly all positively stained segments, there
as evidence of IHC staining in the dense adventitia,
ndicating inflammatory/atheroma components.
tatistical analysis. Data were analyzed using Sigma Stat,
ersion 2.03 statistical software (SPSS Inc, Chicago, Illi-
ois). The results are expressed as the mean  SD.
ifferences between groups were analyzed using one-way
nalysis of variance with the Student-Newman-Keuls
ethod. A p value 0.05 was considered statistically
ignificant.
ESULTS
reliminary investigation. IVUS DETECTION OF ANTI-
IBRINOGEN ELIP ATTACHED TO INJURED ENDOTHELI-
M. In the first two animals, blinded observers were able to
isibly detect injured endothelial enhancement by anti-
brinogen ELIP, 5 min after intra-arterial injection, in six
d left femoral artery. Expression of intercellular adhesion molecule stains
ellular proliferation of the intima from the atheroma.ducef eight arteries. Figure 2 demonstrates IVUS images of a
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Molecular IVUS Imaging of Atheroma Components February 4, 2004:453–60ight femoral artery, showing enhancement of injured en-
othelium by anti-fibrinogen conjugated ELIP. On the left
s an image after saline injection and on the right 5 min after
nti-fibrinogen ELIP (8 mg). With ELIP enhancement,
he intima is better identified, separated from the black
edia and the outer white adventitia, which is also more
learly identified. Blooming from the ELIP intimal en-
ancement makes the media smaller than in actuality,
lthough separation of the intima, media, and adventitia
emains.
IDEODENSITOMETRIC ANALYSIS OF BALLOON-INJURED
NDOTHELIUM. The MGS changes after anti-fibrinogen
LIP injection at 5 min are shown in Table 1. The MGS
ncrease of all injured segments observed to be enhanced by
LIP versus saline was 22  5%, and that of all non-
njured, non-enhanced segments was2 6% (p 0.001).
theroma enhancement by ELIP/molecular expression.
ISUAL DETECTION OF ATHEROMA AFTER CONJUGATED
LIPS. Visible detection of atheroma enhancement with
VUS was seen 5 min after intra-arterial injection of
nti-VCAM, anti-ICAM, anti-TF, anti-fibrin, and anti-
igure 2. The intravascular ultrasound (IVUS) images of a right femoral
rtery showing enhancement of injured endothelium by anti-fibrinogen
onjugated echogenic immunoliposome (ELIP). (a) After saline injection
nd (b) 5 min after 8 mg anti-fibrinogen conjugated ELIP. Because of
looming of the endothelium from ELIP enhancement, the media is the
lack rim and some of the white rim from the intima. Arrows indicate
nhanced endothelium. A  dense adventitia; I  intima; M  media.
Table 1. MGS Values of Injured (Enhanced) E
Enhanced) Segments 5 Minutes After 5 mg A
MGS Injured Segments
Saline Anti-Fbgn E
Pig 1
RC 47  8 56  10
LC 44  6 58  11
RF 38  7 47  8*
LF 47  6 56  6*
Pig 2
RC — —
LC 56  10 65  9*
RF 67  9 82  17
LF — —
*p 0.05 versus saline controls. †p NS versus saline contro
segments/artery).
ELIP  echogenic immunoliposome; Fbgn  fibrinogen
RC  right carotid; RF  right femoral.brinogen conjugated ELIPs. The observers saw no differ-
nce between the 5- and 10-min time points. In 30
egments (9 arteries), atheroma enhancement by conjugated
LIP was seen. After unconjugated ELIP injection, the
bservers reported no enhancement of any of the 140
egments assessed. Figure 3 demonstrates the IVUS images
f a left carotid artery, showing atheroma expressing
CAM by anti-VCAM conjugated ELIP, and Figure 4
emonstrates the IVUS images of a right femoral artery,
howing enhancement of atheroma expressing ICAM by
nti-ICAM conjugated ELIP (part a, after saline injection;
, 5 min after unconjugated ELIP [8 mg]; and c, 5 min after
onjugated ELIP [8 mg]). Figure 4 demonstrates adventitial
nhancement of anti-ICAM conjugated ELIP in addition
o intimal highlighting, as confirmed by IHC staining. As
n Figure 2, in both of the Ab-conjugated ELIP images, the
ntima is clearly outlined and separated from the black
ntima, although some blooming from the intimal enhance-
ent makes the media smaller than in actuality. There was
ariable highlighting of the adventitia with the various
b-conjugated ELIPs, compatible with variable inflamma-
ory component deposition in the dense adventitia and
LIP access to the dense adventitia via the vasovasorum.
IDEODENSITOMETRIC ANALYSIS OF ELIP ATHEROMA EN-
ANCEMENT. The IVUS MGS values at 5 min for visually
nhanced segments are outlined in Table 2. Saline and
nconjugated ELIP were used as controls. Nine arteries had
egments visually observed to be enhanced. In one artery,
he MGS of conjugated ELIP, and in two arteries, the
GS of unconjugated ELIP, could not be assessed reliably
ue to stagnant flow obscuring the endothelium. All en-
anced segments had MGS different from saline and
nconjugated ELIP. The combined average MGS change
f all the enhanced segments after conjugated ELIP injec-
ion versus saline was 39 18% (p 0.001; n 8 arteries),
ompared with the combined average MGS change of the
nconjugated ELIP versus saline of 1  4% (p  NS; n 
arteries).
thelial Segments Versus Non-Injured (Non-
ibrinogen ELIP Injection
MGS Non-Injured Segments
Saline Anti-Fbgn ELIP
51  13 49  13†
41  5 39  4†
38  4 37  5†
32  2 32  2†
60  6 66  5*
59  11 53  9†
91  30 92  31†
58  15 54  9†
ta are presented as the mean value SD (n 12 endothelial
left carotid; LF  left femoral; MGS  mean gray-scale;ndo
nti-F
LIP
*
*
*
ls. Da
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February 4, 2004:453–60 Molecular IVUS Imaging of Atheroma ComponentsThe IVUS MGS values for non-enhanced segments at 5
in are presented in Table 3. Seventeen arteries contained
t least one segment not observed to have been enhanced
fter ELIP injection. The MGS values of all segments after
nconjugated ELIP and conjugated ELIP were not differ-
nt from those with saline. The average MGS change of the
on-enhanced segments after conjugated ELIP injection
ersus saline was 4  6% (p  NS; n  17 arteries),
ompared with the average MGS change of the unconju-
ated ELIP versus saline (1  7%; p  NS; n  14
rteries).
NHANCEMENT BY IVUS IMAGING VERSUS IHC MOLECULAR
XPRESSION. A comparison of ELIP enhancement and
HC molecular expression is shown in Table 4. All arteries
bserved to have segments that were enhanced by ELIP had
orresponding IHC expression of the target molecule. In
ine of 11 arteries that did not have ELIP atheroma
nhancement, no expression of the target molecule was
etected. Two of 11 arteries that did not have ELIP
theroma enhancement had expression of the target mole-
ule in one (VCAM-1) and three (ICAM-1) segments,
espectively.
ISCUSSION
e have demonstrated and confirmed by IHC that acous-
ically reflective ELIP can produce rapid, specific ultrasound
nhancement of molecular endothelial/atheroma targets.
igure 3. The intravascular ultrasound (IVUS) images of a left carotid a
VCAM) conjugated echogenic immunoliposome (ELIP). (a) After saline
CAM-conjugated ELIP. Arrows indicate enhanced atheroma. Abbrevia
igure 4. The intravascular ultrasound (IVUS) images of a left carotid a
ICAM) conjugated echogenic immunoliposome (ELIP). (a) After saline
CAM-conjugated ELIP. Notice the additional enhancement of the a
nhancement by ELIP, as confirmed by immunohistochemistry (see Fig. 1). Arur discussion focuses on the implications of our results,
actors influencing our results, and potential applications.
We have previously quantified the ELIP enhancement of
brin in vitro by IVUS imaging (20). We have qualitatively
emonstrated in vivo non-specific acoustic image enhance-
ent with anti-fibrinogen and anti-ICAM conjugated
LIPs using transvascular and IVUS (4). We have per-
ormed previous experiments to demonstrate the link be-
ween Ab-labeled liposomes and fibrin using scanning
lectron microscopy (3). We have demonstrated in a flow
hamber that 1) anti-fibrinogen conjugated liposomes retain
heir adherence to fibrin under physiologic sheer/flow (17)
nd 2) ELIPs retain their echogenic properties after 9 min
f physiologic sheer (20). These studies provide evidence for
LIP targeting under physiologic conditions while retain-
ng echogenic characteristics.
Our previous studies involved a more aggregated prepa-
ation of conjugated ELIP. By examining the components
nd physical properties of ELIPs, we have altered our
riginal ELIP preparation and developed a new preparation
hat is subject to less aggregation (unpublished data) and
lso has higher acoustic reflectivity (21).
Other investigators have been studying ultrasound con-
rast agents for targeted highlighting. Lanza et al. (22–24)
rst demonstrated that a multi-step, acoustically active
iotinylated, lipid-coated, perfluorocarbon nanoemulsion,
s an ultrasound contrast agent, could be successfully tar-
eted to dog thrombi in vivo. They have also characterized
showing atheroma enhancement by anti-vascular cell adhesion molecule
tion, (b) 5 min after 5 mg unconjugated ELIP, and (c) 5 min after 5 mg
as in Figure 2.
showing atheroma enhancement by anti-intercellular adhesion molecule
ion, (b) 5 min after 5 mg unconjugated ELIP, and (c) 5 min after 5 mg
itia outside the area highlighted by the arrows, indicating adventitialrtery
injec
tionsrtery
inject
dventrows indicate enhanced intima/atheroma. Abbreviations as in Figure 2.
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Molecular IVUS Imaging of Atheroma Components February 4, 2004:453–60his contrast agent and demonstrated that it can infiltrate
rterial walls and localize TF expression (25).
Unger et al. (26) created a targeted perfluorobutane-
ontaining microbubble formulation (aerosomes) and dem-
nstrated that this agent was able to bind to thrombus in
itro (27).
The time frame of image enhancement with our ELIP
reparation is more rapid than others have previously
escribed with other contrast agents requiring multiple-step
rocesses, which require 20 to 30 min to produce discern-
ble enhancement (24,28). The rapid enhancement seen
ith ELIP may be partly due to the single-step targeting.
nhancement continued at least to 10 min after injection,
emonstrating continuing enhancement over time. This
mplies ongoing binding of ELIP under physiologic flow
onditions. The maintenance of echogenicity also demon-
trates structural stability of the ELIPs once they attach to
he target.
tudy limitations. Some limitations and unexpected ob-
ervations were noted. In a few arteries, the endothelium/
able 2. Intravascular Ultrasound MGS Values for Visually Enha
Molecular Target Animal/Artery
Atheroma
Type
CAM-1 4/RF NO, IT
5/LF NO, IT
5/RC NO, IT
F 3/RF BOS
CAM-1 3/LC O, IT
6/RF NO, IT
ibrin 5/LC NO, IT
ibrinogen 4/LC O, IT
p  NS versus saline controls. †p  0.05 versus saline and unconjugated ELIP con
BOS  balloon overstretch; ICAM-1  intercellular adhesion molecule-1; IT 
ascular cell adhesion molecule-1; other abbreviations as in Table 1.
able 3. Intravascular Ultrasound MGS Values for Visually Non-
Molecular Target Animal/Artery
Atheroma
Type
CAM-1 4/RF NO, IT
5/LF NO, IT
5/RC NO, IT
5/RF NO
4/LF O, IT
F 3/RF BOS
3/RC BOS
3/LF O, IT
CAM-1 3/LC O, IT
6/RF NO, IT
3/LF O, IT
6/LF O, IT
6/LC O, IT
7/RF NO, IT
7/LF O, IT
7/RC O, IT
ibrin 4/RC NO
p  NS versus saline controls. Data are presented as the mean value  SD.
Abbreviations as in Tables 1 and 2.theroma was unable to be visualized due to either slow flow
bscuring the image or occlusive disease making the area of
isease difficult to see if immediately adjacent the IVUS
atheter. Additionally, interpretation of the IHC staining in
ome segments was difficult because of preparation artifacts.
The choice of control was difficult. We have demon-
trated in previous work that non-specific binding of im-
unoglobulin G to fibrin was enough to produce attach-
ent to target molecules. In vitro, this can be controlled
ith bovine gamma globulin that blocks non-specific bind-
ng. In vivo, the cross reactivity of nearly all unrelated Abs
n this animal model has not been assessed. As a result,
ontrolling for unrelated Ab cross reactivity with the specific
olecular target was very difficult. For this reason, uncon-
ugated ELIPs were used as controls. The lack of enhance-
ent by conjugated ELIP in the absence of positive IHC
taining confirms minimal non-specific binding.
We were fortuitous in finding that the rabbit anti-
brinogen conjugated ELIP not only binds fibrin specifi-
ally, but can also be injected intravenously to target left
Atheroma Segments
MGS Enhanced Segments
Saline
Unconjugated
Liposomes
Conjugated
Liposomes
66  9 68  16* 92  20†
57  17 56  8* 97  19†
72  11 74  11* 94  20†
103  14 — 124  20†
118  25 125  22* 160  22†
108  20 115  22* 142  23†
70  12 69  15* 87  26†
60  17 — 101  29†
Data are presented as the mean value  SD.
l thickening; NO  non-occlusive; O  occlusive; TF  tissue factor; VCAM-1 
anced Atheroma Segments
MGS Enhanced Segments
Saline
Unconjugated
Liposomes
Conjugated
Liposomes
58  11 57  13* 62  13*
93  19 96  11* 89  14*
59  10 62  11* 64  10*
69  8 72  13* 68  9*
72  12 77  26* 83  22*
106  14 — 108  23*
138  16 — 131  21*
125  17 128  19* 121  10*
116  18 106  15* 105  25*
120  20 126  18* 129  29*
121  18 132  21* 122  23*
122  17 113  15* 116  16*
120  14 125  26* 125  26*
56  17 59  19* 59  22*
86  20 81  20* 90  16*
51  15 51  9* 54  14*
80  21 — 87  24*nced
trols.
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February 4, 2004:453–60 Molecular IVUS Imaging of Atheroma Componentsentricular thrombi (25). We have also demonstrated no
oagulation of the rabbit anti-fibrinogen conjugated ELIP
n the presence of free fibrinogen. Although useful for our
xperiments, we will have to use a monoclonal fibrin-
pecific Ab for ELIP targeting in humans.
Due to histologic processing artifacts and shrinkage, we
ere unable to make an exact spatial correlation between
VUS images and IHC sections. This reduced the ability of
he protocol to quantitate specificity and sensitivity with
espect to IHC binding. Despite this, enhanced segments
id appear to correspond to IHC staining data, and non-
nhanced segments corresponded to non-IHC staining
ithin each arterial segment, which provides good evidence
f molecular imaging. Two arteries did express target
olecules in one and three segments but were not enhanced
y ELIP. Slow luminal flow in these two arteries may have
bscured IVUS atheroma visualization. Further studies will
eed to be conducted to demonstrate the potential of ELIPs
o provide molecular atheroma imaging when injected
ntravenously and to quantitate molecular atheroma en-
ancement using transcutaneous ultrasound.
tudy implications. The implications and potential appli-
ations of these data are important. Echogenic immunoli-
osomes may now be developed for use in the cardiac
atheterization laboratory to stage atheroma. Recent ad-
ances by others in advanced IVUS image analysis, com-
ined with these targeted molecular contrast agents, may
rovide powerful tools to better localize and quantitate
laque components (29,30). This includes characteristics of
laques (e.g., fibrinous craters, lipid lakes under small rims
f atheroma) that may make them vulnerable to plaque
upture and embolism. The ability to stage atheroma com-
onents may facilitate application of more directed therapy,
s non-echogenic liposomes have already been evaluated as
rug (31) and gene delivery systems (32). Recent studies
ave demonstrated other cardiovascular uses of targeted
LIPs for transthoracic imaging of left ventricular thrombi
15). Furthermore, targeted ultrasound contrast agents are
Table 4. Comparison of Echogenic Immunolip
Ultrasound and Immunohistochemical Molecu
Molecular Target
Arterial segments enhanced by conjugated ELIP
ICAM-1
TF
VCAM-1
Fibrin
Fibrinogen
Arterial segments not enhanced by conjugated ELIP
ICAM-1
TF
VCAM-1
Fibrin
  enhanced;   not enhanced; n/a  not assessable/unot limited to cardiovascular medicine, and by interchang-ng Abs, ELIPs can be targeted to any molecule for
athologic ultrasound image enhancement.
onclusions. We have demonstrated rapid IVUS image
nhancement of injured endothelium/atheroma by ELIPs in
n in vivo miniswine atheroma model. Image enhancement
as confirmed quantitatively. Confirmation by IHC docu-
ented ELIP targeting. These data help to further the
tility of targeted ultrasound contrast agents for molecular
theroma component enhancement.
eprint requests and correspondence: Dr. David D. McPher-
on, Department of Medicine, Division of Cardiology, Northwest-
rn University, 251 East Huron, Galter 8-230, Chicago, Illinois
0611-2908. E-mail: d-mcpherson@northwestern.edu.
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